CD Biosynsis offers advanced CHO (Chinese Hamster Ovary) Cells CRISPR-Cas9 Genome Editing Services, providing precise and highly efficient genetic manipulation in this premier mammalian host. CHO cells are the industry workhorse for producing complex therapeutic proteins, monoclonal antibodies (mAbs), and biosimilars. Our services leverage the power of CRISPR-Cas9 to induce targeted DNA double-strand breaks (DSBs), enabling highly efficient Homology-Directed Repair (HDR) for precise gene knock-in, and reliable Non-Homologous End Joining (NHEJ) for gene knockout. We provide end-to-end solutions, from rational target design and gRNA optimization to stable integration and multi-gene editing, accelerating the development of superior CHO cell lines for enhanced yield, improved product quality (e.g., glycosylation), and robust bioprocessing performance.
Get a QuoteCRISPR-Cas9 editing is essential for optimizing CHO cells, which typically have complex, pseudo-tetraploid genomes and require high stability for industrial use. Our services overcome the low efficiency of traditional methods by using optimized delivery strategies (plasmid, virus, or RNP) and specialized gRNAs tailored for the CHO genome. This ensures accurate manipulation, from inserting highly expressed antibody genes into genomic safe harbor loci to knocking out genes like GS or DHFR for selection and amplification. This capability is critical for complex bioprocessing projects that demand fast, clean, and stable genomic modifications to meet regulatory and quality standards.
CRISPR-Cas9 System
Standard editing platform for targeted DNA double-strand breaks (DSBs), optimized for efficient CHO cell transformation using RNP, plasmid, or lentivirus delivery methods.
Multiplex gRNA Assembly
Construction of gRNA arrays for the simultaneous targeting of multiple genes (e.g., knocking out fusion genes or multiple protease genes) to accelerate chassis engineering.
HDR Repair Template Design
Design of large DNA donor templates (up to 10kb) with optimized homology arms to maximize the rate of accurate gene insertion (knock-in) at targeted loci.
Gene Knockout (KO)
Permanent deletion or disruption of target genes (e.g., pro-apoptotic genes, proteases) via NHEJ, resulting in high cell viability or improved product stability.
Targeted Gene Knock-in
Accurate integration of large expression cassettes (e.g., mAb light and heavy chains) into genomic safe harbor loci for stable, high-level expression.
Point Mutation & Tagging
Introduction of precise single-nucleotide polymorphisms (SNPs) or fluorescent/affinity tags to endogenous genes for pathway analysis or protein purification.
High-Yield MAb Production
Stable integration of antibody expression cassettes into highly expressed loci to maximize the specific productivity (Qp) of the cell line.
Glycosylation Engineering
Knockout of native glycosylation genes (e.g., FUT8 or GNAT) and knock-in of human glycosylation enzymes to achieve desired Human-like Glycoprofiles.
Enhanced Cell Line Stability
Editing pro-apoptotic or protease genes to extend cell culture longevity and reduce product degradation during large-scale fed-batch production.
A systematic process for rational design, precise editing, and stable clone isolation.
1. Rational Design & RNP Preparation
2. Transfection & Editing
3. Single Cell Cloning & Screening
4. Clone Isolation & Verification
Identify target locus (KO or KI site). Design gRNA(s) for high on-target specificity in the complex CHO genome.
Prepare the Cas9 enzyme/gRNA Ribonucleoprotein (RNP) complex for transient, high-efficiency delivery.
Design the large DNA repair template (donor DNA) with necessary selection markers (if KI).
Deliver the RNP complex (and donor DNA for KI) into the CHO host cell line via optimized electroporation or lipofection protocols.
Culture cells for repair mechanisms (NHEJ or HDR) to finalize the genomic edit.
Apply antibiotic selection (e.g., Puromycin) or metabolic selection (e.g., Methotrexate) to enrich for edited clones.
Genotype verification via junction PCR and definitive sequencing of the edited locus to confirm clean edit.
Phenotypic validation of the final clone for titer (Qp), stability, and product quality.
Delivery of the verified CHO master cell bank (MCB) and complete documentation.
High Precision, Low Off-Target
Preference for RNP delivery and rationally designed gRNAs ensures transient activity and high on-target specificity, critical for the complex, polyploid CHO genome.
Stable Chromosomal Knock-in
CRISPR-guided HDR ensures stable integration of antibody/protein genes into specific genomic safe harbor loci, guaranteeing consistent expression and regulatory compliance.
Product Quality Engineering
Expertise in editing glycosylation genes (e.g., FUT8 or GNAT) to precisely control N-glycan profiles, achieving optimal homogeneity and human-like glycosylation.
Extended Culture Viability
Targeted knockout of pro-apoptotic genes (e.g., Bax, Bak) enhances cell culture longevity, leading to higher final product yield in fed-batch bioreactors.
1. Why are CHO cells the preferred host for biotherapeutics?
CHO cells are mammalian, enabling them to perform the complex protein folding, assembly, and post-translational modifications (PTMs), including human-compatible glycosylation, required for monoclonal antibodies and therapeutic proteins.
2. What is a "genomic safe harbor" locus in CHO cells?
A genomic safe harbor is a specific, transcriptionally active region of the CHO genome (like the hprt or ROSA26 sites) where a gene can be inserted (knock-in) to ensure high and stable expression without disrupting essential host genes.
3. What is the advantage of using RNP (Ribonucleoprotein) delivery?
RNP (Cas9 protein complexed with gRNA) provides transient, fast-acting editing activity. This minimizes the time the Cas9 is active in the cell, significantly reducing the risk of off-target mutations compared to using plasmid or viral delivery methods.
4. Can you perform multiple gene knockouts simultaneously?
Yes. We use multiplex gRNA systems to simultaneously target and disrupt multiple genes (e.g., multiple protease genes or cell death regulators) via the Non-Homologous End Joining (NHEJ) pathway to accelerate chassis development.
5. How is product quality controlled and improved through editing?
We modify glycosylation pathways (e.g., knocking out fucosylation genes like FUT8) to control the glycan structure, which directly impacts the therapeutic efficacy, half-life, and immunogenicity of the final mAb product.
6. What is the difference between Gene Knockout (KO) and Gene Knock-in (KI)?
KO removes or disrupts a gene (via NHEJ), often to eliminate unwanted function (e.g., apoptosis). KI inserts a new, large gene cassette (e.g., the therapeutic gene) precisely at a chosen site (via HDR), often to guarantee stable expression.
7. What is the final output of the service?
We deliver a fully characterized and verified CHO master cell bank (MCB), along with a comprehensive report detailing the gRNA design, editing strategy, genomic verification data, and final clone stability/titer.
8. How do you ensure the stability of the engineered CHO cell line?
Stability is ensured by performing the knock-in into defined, transcriptionally active genomic loci via HDR, avoiding random plasmid integration that leads to gene silencing and unstable expression over time.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.